Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -28.46
- Piotroski Score 2.00
- Grade Buy
- Symbol (KTRA)
- Company Kintara Therapeutics, Inc.
- Price $0.20
- Changes Percentage (3.72%)
- Change $0.01
- Day Low $0.17
- Day High $0.21
- Year High $4.59
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/08/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.32
- Trailing P/E Ratio -0.09
- Forward P/E Ratio -0.09
- P/E Growth -0.09
- Net Income $-14,649,000
Income Statement
Quarterly
Annual
Latest News of KTRA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Brie Larson to make her West End debut in revenge tragedy Elektra
Brie Larson, Oscar-winning actress, will make her West End debut in the play Elektra in Brighton and London. Directed by Daniel Fish and adapted by poet Anne Carson, the production explores the inters...
By The Guardian | 1 week ago -
Dan Hurley Backtracks on NBA Coaching Pursuit After Turning Down Lakers
UConn coach Dan Hurley explains why he turned down the Lakers' head coaching job, preferring to stay with his college team to mentor young players. Despite Lakers' interest, Hurley values impact on st...
By Newsweek | 2 weeks ago -
Darktrace CEO out as takeover deal confirmed
POPPY Gustafsson steps down from Darktrace as Thoma Bravo prepares to acquire the company for £4.3 billion. She is succeeded by COO Jill Popelka....
By Yahoo! Finance | 3 weeks ago